Phanes Therapeutics, Inc., a San Diego CA- and Shanghai, China-based company that specializes in innovative drug discovery in immuno-oncology, raised $40M in Series B funding.
The round was led by Sequoia Capital China with participation from new investors and current shareholders.
Led by Ming Wang, PhD/MBA, CEO, Phanes Therapeutics is a biotech company focused on discovery and development of innovative biologic drugs in oncology and eye diseases.
The company intends to use the funds to advance several preclinical programs to clinic, expand the research and clinical teams, and support the advancement of research projects in the PACbody™ and ATACCbody™ platforms.
FinSMEs
27/05/2021